BIGBEAR
PHARMACEUTICALS
Osimertinib is a third-generation targeted therapy for lung cancer, specifically designed to treat non-small cell lung cancer driven by specific genetic mutations.
AuthenticGuaranteeFast DeliveryPrivacy Osimertinib is indicated for the treatment of various types of non-small cell lung cancer (NSCLC). Before initiating treatment, an FDA-approved diagno···【Read More】
Update: 06 Mar,2026Source: Haiou HealthViews: 74
Since its FDA approval in the United States in 2015, Osimertinib has been widely used and recognized globally. In China, Osimertinib is marketed and i···【Read More】
Update: 06 Mar,2026Source: Haiou HealthViews: 71
Osimertinib is a targeted therapy, belonging to the third-generation EGFR (epidermal growth factor receptor) tyrosine kinase inhibitors.Side effects r···【Read More】
Update: 06 Mar,2026Source: Haiou HealthViews: 71
Osimertinib, as a third-generation EGFR-TKI, has become a breakthrough drug in the treatment of non-small cell lung cancer (NSCLC) due to its highly e···【Read More】
Update: 06 Mar,2026Source: Haiou HealthViews: 71
On April 18, 2018, AstraZeneca announced that the U.S. Food and Drug Administration (FDA) had approved osimertinib for first-line treatment of patient···【Read More】
Update: 06 Mar,2026Source: Haiou HealthViews: 72
On November 16, 2015, the U.S. Food and Drug Administration (FDA) granted accelerated approval to osimertinib for the treatment of patients with advan···【Read More】
Update: 06 Mar,2026Source: Haiou HealthViews: 72
Osimertinib is a targeted therapy for non-small cell lung cancer. Common side effects include skin reactions (rash, dryness), gastrointestinal discomf···【Read More】
Update: 06 Mar,2026Source: Haiou HealthViews: 72
Copyright2024@ BIGBEAR All right reserved BIGBEAR
